News and Insights for Psychiatric Pharmacists

AAPP and the AAPP Foundation are pleased to be offering a complimentary, 2-hour workshop: Cultivating Expertise: Enhancing Presentation Design and Speaker Development in Psychiatric Pharmacists. Earn ACPE credit and make yourself a standout voice in the field of psychiatric pharmacy!

Dr. Jerry McKee, PharmD, MS, BCPP, explains the difference between BCPP re-testing versus recertification.

Improve your peer review skills! Discover the components to evaluate, the role of the peer reviewer, the skills necessary to critically evaluate a manuscript, and how to provide feedback to authors and journal editors.

Kelly Gable, professor and director of well-being and resilience at Southern Illinois University Edwardsville School of Pharmacy, and member of the AAPP Board, discusses her own cancer journey and how pharmacists need to be more involved and proactive in patients' mental health.

AAPP supports defining opioid use disorder as a treatable medical condition with a biological basis that is often associated with a history of trauma. Access to MOUD is essential in reducing deaths related to opioid overdose and landmark studies clearly demonstrate that the benefits of MOUD outweigh the risks. Psychiatric pharmacists are encouraged to use this policy brief to support your own advocacy for this gold-standard treatment.

Evidence is insufficient for the use of cannabis or cannabinoids for most medical indications.

New analysis from a WHO global expert committee on vaccine safety has found that, based on available evidence, no causal link exists between vaccines and autism spectrum disorders (ASD). The conclusion reaffirms WHO’s position that childhood vaccines do not cause autism.

As I look back on this year for the American Association of Psychiatric Pharmacists (AAPP), I am deeply grateful for the achievements that have strengthened our association and advanced our shared mission.

Evidence is insufficient for the use of cannabis or cannabinoids for most medical indications. Clear guidance from clinicians is essential to support safe, evidence-based decision-making.

This study used our peer-reviewed model of the US opioid crisis to demonstrate how a falling at-risk population combined with probable plateauing of the mortality rate produced the recent decline in US overdose deaths.

ED-initiated XR-BUP was associated with substantial reductions in opioid and polysubstance use during the first week post-discharge, supporting its role in early overdose risk mitigation and highlighting its value as an ED-based intervention for opioid use disorder.

In this cohort study including children prenatally exposed to SSRIs, additional exposure to SSRIs through breastfeeding was not associated with reduced IQ scores.

Antipsychotic prescriptions for older adults in the U.S. have increased in the last decade, especially from long-term care pharmacies. That’s according to a study published in JAMA Psychiatry, which found that among adults aged 65 and older, rates of antipsychotic use increased from 2.67 per 100 people in 2015 to 4.05 per 100 in 2024. Researchers analyzed a decade of antipsychotic prescription claims from around the country for more than 8 million people aged 65 or older. Long-term use increased over the years, as did prescriptions from long-term care pharmacies. Prescriptions from psychiatrists declined. The patterns suggest an increase in chronic conditions or cognitive impairments among older adults, the authors write. They believe the increase in prescriptions emphasize the importance of improving mental health care and behavioral interventions for this population.

Despite strong evidence, there is a large implementation gap in both high-income and LMIC settings.

The analysis directly compared the effectiveness of different strategies on the rate of relapse either with or without psychological support.

Registration is open for AAPP 2026 in Bellevue, Washington, on Seattle's Eastside! Plan to attend along with 800+ psych pharmacists and take advantage of 23+ hours of CE and 10 hours of BCPP recertification programming. Registration rates increase March 20, 2026.

We're pleased to give AAPP members a sneak peek at future Annual Meeting locations! Which city are you the most excited for?

Pharmacy careers change lives. Learn if a job as a pharmacist is right for you and how you can help people live better, healthier lives. #Pharmacy #PsychPharm

Barriers to access shouldn’t stand in the way of opportunity. Student Registration Grants supported by the AAPP Foundation help aspiring psychiatric pharmacists attend key events and grow professionally. Support the next generation of psychiatric pharmacy leaders. #AAPPFoundation #AdvancingPsychPharmacy

Psychiatric clinical pharmacists are pivotal in the care of patients with substance use disorders to advocate for and initiate medications for alcohol use disorder (MAUD) and opioid use disorder (MOUD). Pharmacists are uniquely positioned to counsel patients on MAUD/MOUD, provide naloxone on discharge, and further facilitate transitions of care by ensuring affordability of these medications and confirming continuity via outpatient follow up.

Clinical pearls are an important part of medical education where psychiatric pharmacists share their experiences with unique patient cases and/or clinical challenges. The Program Committee is pleased to once again be accepting submissions for 13-minute presentations at AAPP 2026 on Tuesday, April 21, in Bellevue, Washington (on Seattle's Eastside). Pharmacists should submit their clinical pearl online for consideration by the January 8, 2026, deadline, and up to 3 presentations will be selected for the Clinical Pearls session.

Ready to lead the way in psychotropic LAI implementation? This 6-part educational series equips learners with advanced knowledge across clinical care, patient engagement, leadership advocacy, and financial sustainability. #LAIs #psychiatricpharmacy #CE

Clinical effectiveness was supported in most studies, particularly for promoting abstinence and medication adherence.

This study’s results support advanced psychiatric-mental health practice nurses and emergency and psychiatric-mental health clinical nurses in improving the quality of care and safety for this vulnerable population.

Evidence suggests that the use of serotonergic and non-serotonergic psychedelics for the treatment of SUD may provide advantages over traditional therapeutics.

AAPP supports access to behavioral interventions, including parent training in behavior management, and stimulant treatment for youth with functionally impairing symptoms of attention-deficit/hyperactivity disorder (ADHD) as the most effective treatment for ADHD given their associated improvement in academic, social, and developmental functioning. Psychiatric pharmacists are encouraged to use this policy brief to support your own advocacy for this gold-standard treatment.

There are many patients with serious mental illness and substance use disorder who may benefit from a long-acting medication but are not offered a trial. Long-acting medications (LAMs) have been underutilized for these conditions, despite convincing evidence of their superior outcomes compared to oral medications.

Following overnight cannabis abstinence, smoking cannabis acutely decreased alcohol consumption compared to placebo.

This systematic review and meta-analysis demonstrates that CM effectively reduces alcohol use among adults with UAU.

These findings suggest VLNC cigarettes may aid broadly in cessation efforts and demonstrate feasibility for larger trials.

You can submit abstracts online for the 2026 AAPP Annual Meeting from now through January 8, 2026. Accepted abstracts will be displayed during the meeting at the Hyatt Regency Bellevue in Bellevue, Washington, held April 19-22, 2026.

This free pharmacist toolkit on benzodiazepine taper includes populations at risk for complications, screening and diagnosis, benzodiazepine withdrawal, treatment, special populations, harm reduction, clinical pearls, authors experience, and references.

Whether you're improving transitions of care, managing special populations, or building a profitable clinic - this program has you covered! Register now and gain up to 9 CE credits by completing modules of interest. #LAI

There were modest increases in methadone and buprenorphine use per 1000 Medicaid enrollees from 1999 to 2010.

Diversity, Equity, and Inclusion aren’t just buzzwords—they are essential to progress. Support DEI Grants that help psychiatric pharmacy become a more inclusive and representative profession. Your contribution can help amplify new voices and perspectives. #AAPPFoundation #AdvancingPsychPharmacy

Planning to sit for the BCPP exam? We've got resources! #BCPP #AAPP #examprep #psychpharmacy

Earn up to 5.5 ACPE contact hours during this on-demand, seven-part educational series! Webinars are immediately accessible. Register and start today!

Giving Tuesday is almost here! The campaign starts at midnight tonight, and the world is ready to make a difference. To support the AAPP Foundation and help us reach our annual fundraising goal of $75,000, please make your donation online or by mail to: AAPP Foundation 8055 O Street, Suite S113 Lincoln, NE 68510 Your donation will make a difference! Thank you for partnering with us to advance psychiatric pharmacy.

AAPP supports the continued availability of SSRIs as an option for treatment of moderate to severe symptoms of perinatal depression and anxiety. Any concerns regarding risks of antidepressant use in this population must be weighed against the risks associated with suboptimal management of psychiatric symptoms. Psychiatric pharmacists are encouraged to use this policy brief to support your own advocacy for this gold-standard treatment.

The AAPP Resident and New Practitioner Committee recently completed updates to treatment guidelines and pharmacy essentials. These free resources provide references and clinical pearls for practitioners beginning to practice in psychiatry as well as treatment guidelines for anxiety and related disorders, bipolar disorder, depression, medication-induced movement disorders, schizophrenia, seizure disorders, sleep-wake disorders, and substance use disorder.

Be part of defining what’s next for psychiatric pharmacy. A $250/month donation funds “Defining the Future” Research Grants that support pioneering ideas and new models of care. Let’s shape the future—together. #AAPPFoundation #AdvancingPsychPharmacy

Integrating mental health clinicians into primary care expands access to quality mental health care. In this setting, psychiatric pharmacists provide brief psychotropic medication management in collaboration with the primary care physician.

Sophie Robert, BPharm, PharmD, BCPP discusses provider concerns and assumptions about patients' use of psychotropics during pregnancy.

The mock exam is composed of 150 questions based on the content domains and knowledge statements included in the BPS content outline. Register today and practice, practice, practice!

This free toolkit on urine drug screens provides reasons for unexpected results, expected metabolites for opiods with confirmation testing, evaluation of urine, and potential positive results with immunoassays and detection time in the urine.

From inpatient strategies and complex case management to profitability and curriculum integration, this six-part program covers everything pharmacists need to lead with confidence in LAI care. #PatientCare #LAIs #psychiatricpharmacy #CE

AAPP supports funding, access, and delivery of harm reduction services to prevent substance-use related injury, disease, overdose, and misuse. Psychiatric pharmacists are encouraged to use this policy brief to support your own advocacy efforts promoting continued delivery of harm reduction services.

The U.S. administration has continuously chipped away at public health interventions addressing substance use disorders and the opioid crisis, including vital harm-reduction activities.

Unhealthy alcohol use is highly prevalent in the United States, with almost half of all regular consumers reporting binge drinking.

Compared with varenicline alone, combination therapy was associated with statistically significantly higher abstinence rates at the longest follow-up.

The National Council Medical Director Institute (MDI) has released the first-ever standardized performance benchmarks for initiation and continuation of long-acting medications for psychotic disorders, bipolar disorder, opioid use disorder and alcohol use disorder. Past President Jerry McKee represented AAPP on the expert panel while Past President Ray Love contributed as a representative of NASMHPD. Download the MDI report to learn how to implement these benchmarks in your practice.

The helpline is a free, confidential service providing caregiver-led support, tools and strategies, trusted guidance, and connection at every stage of the caregiving journey.

Do you believe psychiatric pharmacists belong on every mental health care team? So do we. Support Outcomes Research Grants that provide the data to make that case. A monthly donation of $1,000 helps fund the next study that changes minds and opens doors. #AAPPFoundation #AdvancingPsychPharmacy

We are proud to partner with the Schizophrenia & Psychosis Action Alliance to offer a 7-part, on-demand educational series! Each module tackles a core challenge in clozapine care, ranging from adverse effect management to monitoring in the post-REMS era, and use in special populations. Register today and get started!

Join us as we unravel the complexities of LAIs! Our Advanced LAI Training Program will equip participants with the tools necessary to lead, innovate, and advance LAI patient care and clinic management. #PatientCare #LAIs #psychiatricpharmacy #CE

This study examined longer-term health outcomes associated with CM treatment for StUD.

Despite widespread attention to the opioid overdose crisis, alcohol use continues to represent a pressing and under-recognized public health challenge.

GLP-1RAs, traditionally prescribed for glycemic control in T2DM and weight management in obesity, are emerging as promising therapies for ASUDs.

Targeted efforts to enhance patient knowledge of MAUD could be a promising strategy for increasing medication uptake.

In this multicenter randomized clinical trial, RI had higher retention than SI overall and in patients who tested positive for fentanyl through extended-release buprenorphine injection 2.

For the fourth time, remote prescribing of controlled substances will be allowed without permanent policy. The Trump administration appears poised to extend a temporary, Covid-era rule allowing health providers to prescribe certain controlled substances, like ADHD medications and treatments for opioid addiction, via telemedicine. Under the current rules, providers can initiate prescriptions for drugs like Ritalin or Adderall for ADHD, or buprenorphine for opioid use disorder, without first examining the patient in-person. A posting on a White House budget website, titled “Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications,” signals that the Trump administration has conceded the regulatory limbo will last at least one more year. It is unclear how the Trump administration might eventually move to finalize regulations for prescribing controlled substances via telemedicine. Among the most debated issues are whether the DEA should differentiate between Schedule II and Schedule III substances (like Ritalin and buprenorphine, respectively), and more generally, how stimulants used to treat ADHD should be regulated.

AAPP supports the use of antipsychotics as the first line treatment for acute and maintenance treatment of schizophrenia, with individual agent and route of administration selected based on patient-specific factors. Psychiatric pharmacists are encouraged to use this policy brief to support your own advocacy for this gold-standard treatment.

Pharmacists practice forensic pharmacy when they care for patients with psychiatric diagnoses who have also been convicted or charged with a crime. The practice settings often include county jails, or state/federal prisons/hospitals or correctional facilities. Pharmacists care for patients in the justice system by reviewing their medication records, making objective/subjective assessments with rating scales and patient interviews, initiating/modifying medication doses, and providing medications-related patient education. Forensic psychiatric pharmacists also can serve as expert witness for lawyers, work for regulatory agencies, or work as a freelance consultant.

Despite widespread health misinformation, 83% of patients still trust their doctors most for medical advice, up from 81% last year.

Clinicians should consider systematically assessing physical function in middle-aged patients who have polypharmacy, to capture physical decline earlier in the lifespan.

This study's findings have implications for disease classification, precision medicine and clinical practice.

It is time to update the directory of Psychiatric Pharmacy Residency Programs. We want your help to self-identify if you participate in residencies. By adding your information to the site, you can raise the visibility of your program among those with a strong interest in psychiatric pharmacy. NEW fields allow you to include your recruitment open-house information.

An umbrella review of nine systematic reviews published in BMJ shows no link between maternal acetaminophen (Tylenol) use during pregnancy and autism or attention deficit hyperactivity disorder (ADHD) in children. The study, led by University of Liverpool researchers, involved a review of research published within the past 10 years, up to September 30, 2025, to evaluate the quality and validity of the evidence and the strength of any association between the use of acetaminophen (sold as paracetamol in many countries) during pregnancy and the risks of autism and ADHD. "The current evidence base is insufficient to definitively link in utero exposure to paracetamol with autism and ADHD in childhood," the researchers concluded. "High-quality studies that control for familial and unmeasured confounders can help improve evidence on the timing and duration of paracetamol exposure, and for other child neurodevelopmental outcomes." They recommended that regulatory agencies, clinicians, pregnant women, parents, and those affected by autism and ADHD be informed about the poor quality of the existing reviews and the likelihood that any positive associations were driven by familial confounding.

Toolkit on Alcohol Use Disorder with quick tips and guideline summaries: Screening/Diagnosis, Alcohol Withdrawal, Maintenance Treatment of AUD, Special Populations and Treatment, Co-occurring Disorders, Harm Reduction Strategies, Resources and References.

Through expert guidance, participants will refine their presentation skills and learn how to captivate audiences. This 2-hour program with ACPE credit provides a unique opportunity to gain practical tools to elevate speaking abilities, enhance your expertise and confidence, and make you a standout voice in the field of psychiatric pharmacy. Don't miss this opportunity to learn!

Dr. Kelly Gable, PharmD, BCPP, gives tips on starting a new practice.

This 2-hour webinar focuses on developing appropriate techniques for answering standardized questions more accurately, identifying common issues in testing that may be hurting your performance, and analyzing your testing performance to improve accuracy, pacing, and endurance. Level up your test-taking skills!

In the past year, the AAPP Foundation has awarded over $70,000 in grant funding and project support. These funds have supported initiatives that expand practice, build evidence, and improve psychiatric pharmacy services. Join us in sustaining this critical work. #AAPPFoundation #AdvancingPsychPharmacy

To address provider cash-flow issues resulting from the expiration of Medicare telehealth flexibilities on Oct. 1, CMS announced Nov. 6 that they will return affected claims submitted on or before Nov. 10 and enable providers to resubmit them with expanded coding that clearly demonstrates eligibility under current law. CMS has been processing claims where eligibility is clear (e.g., behavioral/mental health or specified HCPCS codes), but systems limitations have prevented identification of all payable claims, including some ACO services and behavioral health claims without specific diagnosis codes. To address this, CMS will return held telehealth claims submitted on or before November 10, 2025, for dates of service on or after October 1, 2025. Providers can resubmit these claims following statutory requirements. Providers are directed to updated instructions on the CMS website for resubmission guidance.

AAPP supports access to antidepressants for youth with moderate to severe symptoms of a depressive, anxiety, or obsessive-compulsive-based disorder and reconsideration of the boxed warning on new-onset suicidal thoughts/behaviors given its many unintended consequences and role in accelerating stigma. Psychiatric pharmacists are encouraged to use this policy brief to support your own advocacy for this gold-standard treatment.

The 2026 Physician Fee Schedule (PFS) final rule was released late last week by the Centers for Medicare and Medicaid (CMS). The rule makes direct supervision via telehealth permanent for many services. Additionally, it extends audio-only flexibilities for certain non-behavioral health visits through December 31, 2026. It also proposes new add-on codes for behavioral health integration services within Advanced Primary Care Management (APCM) programs. Please note that the rule does retains some COVID-19-era telehealth restrictions, such as the originating site requirement for certain services. We are pleased that these final provisions overall reflect AAPP’s comments to strengthen behavioral health integration in primary care and expand telehealth flexibilities.

AAPP joined more than 450 organizations in pushing congressional leaders to reinstate lapsed telehealth flexibilities for the long term. Lawmakers have been providing temporary extensions to telehealth policies that, among other flexibilities, allow Medicare beneficiaries to receive medical care in their homes. The policies started during the Covid-19 pandemic, and Congress continued them but never made them permanent. “This cycle of temporary fixes has resulted in patients and providers facing continued disruptions in care,” the groups, co-led by the Alliance for Connected Care, wrote to House and Senate leaders.

AAPP members Andrew Hean, PharmD, APh, BCPS, BCPP, and Winter Roth, PharmD, BCPP, authored this article in the Journal of the American College of Clinical Pharmacy.

Every dollar helps move the profession forward. AAPP Foundation grants support outcomes research, practice expansion, DEI initiatives, and student development—all of which contribute to better care and stronger teams. Give back to move forward. #AAPPFoundation #AdvancingPsychPharmacy

See Employer Benefits by Supporting AAPP Volunteerism "The knowledge gained has been used to change local prescribing policies. My connections provide access to people within the AAPP community with expertise in areas outside my experience." Michael Shuman

Approximately 13 percent of counties had more than half their population living in an area facing a pharmacy shortage last year, according to the National Community Pharmacists. The new data coincides with the NCPA and USC’s launch of the first public mapping tool tracking pharmacy shortage areas and closures over time by state, county and congressional district. AAPP, other pharmacy groups and academics warn that the closures, sometimes the only points of personalized care in communities, could make it more difficult to manage chronic disease, access vaccinations and strain the pharmacy profession.

Dr. Andrew C. Hean, 2023 Defining the Future grant recipient, and his co-authors Jamie Kneebusch,Casey Tiefenthaler, and Kelly C. Lee, recently had their research published! Dr. Hean said, "Thank you again to the foundation for making this research possible, a project that was quite special to me!" Congratulations to this research team, and thank you to our donors who make grants like this possible! You can now read and download the article online.

Long-time AAPP member and the current AAPP Foundation President-Elect, Clayton English, PharmD, BCPS, BCPP, BCGP, FAAPP, is part of a team of SoP faculty researchers at the University of Washington School of Pharmacy that has been awarded a $200,000 Tier 3 pilot research grant from the UW Population Health Initiative. The team’s work aims to address the rise in opioid overdose deaths, increasingly driven by fentanyl. This work is vital to public health. Help us congratulate Dr. English!

If you missed any of the previous Resident Journal Club presentations or would like to revisit a session, recordings are available for you to listen and review at your convenience. Once registered, you can access the recordings, presentations, and article links on the Journal Club page.

This free Pharmacist Toolkit on Addressing Stimulant Shortages is intended to provide an evidence-based guide for thoughtfully converting from one stimulant product formulation to another. Download the toolkit today! #psychpharm #toolkit

Psychiatric pharmacists can function as medical affairs professionals assisting with analyzing and educating providers on clinical data and development of insights that can affect the medical strategy to optimize medications in a company’s psychiatric pipeline. Their training also translates to roles in educating payors on clinical and health economics and outcomes research (HEOR) data that may affect their access algorithms as well as in marketing where on-label data and insights can be leveraged to optimize the success for a company’s marketed psychiatric product.

Gabapentin is approved by the U.S. Food and Drug Administration for treatment of partial seizures and postherpetic neuralgia, but is commonly prescribed for off-label use, including neuropathic pain.

Of those participants who transitioned out of a bridge clinic into community-based SUD care, 78% were successfully connected to ongoing care and 84% were still in care at follow-up.

The AAPP Foundation has accomplished a lot this year, and yet there is still much to do. You can assist us in creating a better tomorrow and help us launch initiatives in the areas of research, education, practitioner development, and our communities. Donate online today!

Stream this expert-led discussion on the expanding role of digital therapeutics in treating mental health conditions. Watch the recording and stay ahead in this fast-evolving field! Visit the course page to watch the webinar or learn more and register.

MHA's State of Mental Health report was released last week and uses the most recent SAMHSA data to highlight and rank states on mental health and well-being. The 2025 report ranks New York, Hawaii, and New Jersey the highest in the nation for mental health - reflecting lower rates of mental illness and higher access to care. Nevada, Arizona and Alabama ranked lowest. A supplemental youth spotlight on mental health advocacy, created by MHA's Young Leaders Council, shows how young people are turning awareness into action and provides strategies and inspiration for other young people to follow.

Module 1 of the TMP Training Series provides tools, tactics, and strategies you need to improve your communication skills and strengthen your status as a trusted messenger.

These results highlight hospitalization as an opportunity to connect patients with IDU-IE to MOUD and preventative care, particularly in rural areas where access to such services may be limited.

Findings suggest that recent SSP use was associated with recent SUD treatment uptake, while recent CLS involvement was not.

“Given this landscape, psychiatric pharmacists play a more important role than ever in patient care. Our knowledge, experience, and understanding of other disease states allows us to support the whole patient.” - Dr. Bostwick

A new Kaiser Family Foundation brief tracks how states are reshaping vaccine policies amid shifting federal guidance. As of Sept. 22, 2025, 26 states had implemented or announced updates expanding access to COVID-19 and other vaccines beyond federal limits. The analysis highlights a sharp partisan divide: Democratic governors lead 23 of those 26 states. The findings suggest vaccine access may increasingly vary by state, reflecting broader political polarization and mirroring national divides in public opinion over vaccination and public health policy.

AAPP supports access to MOUD and defining OUD as a treatable medical condition with a biological basis often associated with a history of trauma. Use AAPP’s policy brief to advocate for this gold-standard treatment.

Glean information and insights from AAPP’s toolkit on Pain Management Pearls for Patients with Chronic Pain or Opioid Use Disorder, our newest valuable resource.

Support the next generation of leaders in psychiatric pharmacy. A $500/month donation funds Collegiate Chapter Impact Grants, which empower student pharmacists to grow as innovators, researchers, and advocates for mental health. Your investment can help shape the future. #AAPPFoundation #AdvancingPsychPharmacy

Dr. Megan Ehret, PharmD, MS, BCPP, explains how to balance your employment expectations with your personal career goals.

The Centers for Medicare and Medicaid Services (CMS) has directed Medicare Administrative Contractors to lift the hold currently in place on some claims with service dates occurring after Oct. 1. This includes telehealth claims that the agency “can confirm are definitively for behavioral and mental health services.” The agency says it will continue to temporarily hold claims for other telehealth services. Many pandemic-era telehealth flexibilities expired Oct. 1, including coverage for home-based and non-rural services. As a reminder, without congressional action to extend telehealth flexibilities, an in-person (i.e., not telehealth) visit is now required within six months prior to a patient receiving their first mental health telehealth service, along with an annual in-person visit requirement for established patients. CMS states it does not believe this requirement applies to beneficiaries who began receiving mental health telehealth services in their homes prior to Oct. 1, 2025. Statutory requirements also exempt telehealth services for someone with a diagnosis of SUD or co-occurring conditions from this requirement. CMS has published a Telehealth Factsheet, along with a Telehealth FAQ updated Oct. 15, 2025.

The first systematic review to examine PrEP interventions among PWUD and identify strategies to enhance adherence.

This study provides empirical support for the theory that AVH are related to abnormalities in the normative suppressive mechanisms associated with inner speech.

An Associated Press investigation found that the wave of legislation has cropped up in most states, pushed by people with close ties to Health and Human Services Secretary Robert F. Kennedy Jr.

In this study, individuals with psychosis reported a large increase in current cannabis use following legalization and commercialization of cannabis in their state, and by larger amounts than previously reported estimates of the general population.

An increase in APC was associated with an increase in the suicide mortality rate at the population level and that the association was similar across sexes.

These findings provide evidence for a relationship between all types of alcohol use and increased dementia risk.

BPS has announced the approval of AAPP as a professional development program (PDP) providers for the contract period beginning January 1, 2026 through December 31, 2030. AAPP will deliver dually certified educational activities for pharmacists certified in pain and psychiatry in partnership with the American Pharmacists Association (APhA), the Society of Pain and Palliative Care Pharmacists (SPPCP), and the American Society of Consultant Pharmacists (ASCP).

The AAPP membership has elected three officers to serve on the 2026-2028 Board of Directors. Assuming their offices effective July 1, 2026, will be Drs. Austin Campbell, Julie Cunningham and Bethany DiPaula. These 3 new members will join Drs. Jolene Bostwick, Kelly Gable, Suzanne Harris and Danielle Stutzman on the Board for 2026-2027.

The Global status report on neurology presents the first comprehensive global assessment of the public health response to neurological disorders under the Intersectoral global action plan on epilepsy and other neurological disorders 2022–31 (IGAP).

The American Psychiatric Association has released an updated guideline for preventing and treating delirium. The previous guideline was published in 1999 with a minor revision in 2010. The updated guideline includes steps aimed at prevention and has a broader scope, targeting not only psychiatrists but also specialists in internal medicine, family medicine, and critical care nursing.

Thanks to member authors Julie Cunningham and Tanya Uritsky, AAPP is pleased to offer this toolkit on Pain Management Pearls for Patients with Chronic Pain or Opioid Use Disorder. The toolkit includes general clinical pearls, information on managing pain and co-occurring MOUD, perinatal pain in patients prescribed MOUD, postpartum opioid-induced respiratory events, and discussion of chronic pain management with a focus on buprenorphine.

The AAPP Foundation is pleased to announce the recipients of the 11th annual Defining the Future Research Grant Awards: Saira Pacheco, PharmD Student, Western University of Health Sciences; Seo Young Park, PharmD, PGY2 Resident, Montefiore Nyack Hospital; Jack Smith, PharmD Student, Wayne State University; Amber Tran, PharmD, PGY2 Resident, Laureate Psychiatric Clinic and Hospital; Mina Wolfe, PharmD, Consultant Pharmacist, North Carolina Association of Pharmacists. Read the full press release!

Your support makes a measurable difference. A $1,000/month donation funds research that helps integrate psychiatric pharmacists into mental health care teams—improving outcomes for patients and the profession. Now is the time to invest in your field. #AAPPFoundation #AdvancingPsychPharmacy

AAPP supports access to behavioral interventions and stimulant treatment for youth with functionally impairing symptoms of ADHD. Use AAPP’s policy brief to advocate for this gold-standard treatment.

At VA Healthcare Systems, psychiatric pharmacists manage medications for military Veterans in outpatient clinics. Under a broad scope of practice (including controlled substance prescribing), psychiatric pharmacists meet one-on-one with Veterans to design personalized treatment plans that optimize symptom control while minimizing side effects.

Young LGBTQ+ people are experiencing worse mental health symptoms, more exposure to conversion therapy, and less access to mental health care, according to an interim report from the Trevor Project.

Guiding principles for state policy on pharmacy personnel-administered vaccines issued by pharmacy vaccine workgroup.

AAPP shares NAMI’s concerns with additional layoffs at SAMHSA and other federal agencies which run programs helping people with mental health conditions. These cuts, coupled with earlier rounds of layoffs and retirements, mean that SAMHSA has reportedly lost nearly two-thirds of its workforce since January. AAPP agrees that such drastic staffing changes threaten to disrupt the availability of the lifesaving resources managed through these agencies.

NAMI’s Federal Shutdown Guide outlines what is known about operations for federal health care and social services that people with mental illness rely on. The guide will be updated as new or additional information becomes available or a deal is reached to re-open the federal government.

A pharmacy-based Vaccine Access Work Group, consisting of representatives from a diverse group of 13 organizations across pharmacy practice settings (including AAPP), jointly published guiding principles for state policy on pharmacy personnel–administered vaccines. This marks an unprecedented level of collaboration between pharmacy professionals, symbolizing a strong commitment from the field of pharmacy to national public health interests. In many states, the authority for pharmacists, pharmacy technicians, and pharmacy interns to administer vaccines is tied directly to recommendations from federal bodies such as the CDC, ACIP, and/or the FDA. As federal processes evolve, recommendations change, and advisory structures shift. Such references can create unintended legal and regulatory ambiguity, reduce flexibility, and delay access to newly authorized and existing vaccines. The core principles proposed in this document aim to address ambiguity in state policymaking regarding pharmacy personnel–administered vaccines, ultimately improving access to essential vaccinations for all Americans and providing guidance for structuring payment for pharmacist-provided services.

AAPP member Kelly Gable reflects on her personal breast cancer journey and advocates for change in a recent article published in the Journal of Patient Experience.

The AAPP Foundation has awarded over $70,000 in research grants and educational support in 2025! We need your support to reach our goal of raising $75,000 to continue these important programs. Help us shape the future of psychiatric pharmacy through these important projects with a donation today.

Pregnant women with OUD face barriers including stigma, childcare demands, provider bias, training gaps, fragmented care, financial and insurance issues, and punitive policies.

Routine pain severity monitoring may provide valuable insight into patient trajectories and support more tailored treatment approaches in OUD.

Pharmacists in several states have recently gained the authority to prescribe for opioid use disorder (OUD). But outdated DEA registration processes were creating roadblocks to pharmacists. AAPP joined other pharmacy associations and states in reaching out, and DEA has responded and agreed to review and update its registration process to reflect pharmacists’ authority under state law. This means fewer barriers for pharmacists and better access to care for patients.

CPE Monitor Plus is an upgraded feature within the ACPE CPE Monitor system that provides you with a more robust and personalized way to manage your professional development. It allows you to access your comprehensive CPE transcript on demand, receive proactive notifications about your license renewal dates, and helps you see how your completed CPE activities align with your specific licensure requirements. The Plus plan is $12 a year.

Advance your profession and help drive innovation in psychiatric pharmacy. Over the past year, the AAPP Foundation has awarded over $70,000 in grant funding to support impactful projects that demonstrate the value of psychiatric pharmacists. Help us keep this momentum going. Consider making a donation today. #AAPPFoundation #AdvancingPsychPharmacy

AAPP supports the availability of SSRIs as treatment option for moderate to severe symptoms of perinatal depression and anxiety with appropriate weighing of all risks and benefits. Use AAPP’s policy brief to advocate for this gold-standard treatment.

Practice, practice, practice! The 150-question mock exam lets you test your knowledge, pacing, and endurance before sitting for the BCPP certification exam. #BCPP #AAPP #examprep #psychpharmacy

About a third of users say they use it to treat mental or physical health issues.

This free collection of essentials provides resources, references, and clinical pearls for practitioners beginning to practice in psychiatry.

There has been confusion and controversy about the appropriate clinical goals for the use of medications such as methadone and buprenorphine. A key question has been when, if ever, to taper and discontinue medication.

This review aims to describe approaches taken by programs in non-clinical settings by identifying key components of delivery models, implementation barriers and facilitators, and outcomes.

A practical guide for providing medications for opioid use disorder (MOUD) and immediate care for patients with opioid use disorder (OUD) in primary care and other ambulatory care settings.

Dr. Raeschell Williams, PharmD, BCPS, BCPP, explains how to discuss illicit or non-prescription drug use with patients.

AAPP supports access to mood stabilizers, including lithium, for the treatment of bipolar disorder. Use AAPP’s policy brief to support your own advocacy for this gold-standard treatment (member only resource).

Studying for the BCPP exam? Test your knowledge with our 150-question mock exam! #psychpharmacy #BCPP #AAPP #BPS #boardcertification

There is a shortage of psychiatric pharmacy providers, and patients have unmet needs that can be filled by these individuals. AAPP's position paper describes the expertise and skills of psychiatric pharmacists and the associated positive outcomes for patients with these disorders. This paper also outlines barriers to the provision of services by psychiatric pharmacists and presents action items aimed at effecting change. Read this position paper to learn more about the value of psychiatric pharmacists as part of the health care team. We hope you will consider exploring psychiatric pharmacy for your career.

The CMS Innovation Center recently released evaluation reports and publications related to the MOM Model, a patient-centered service delivery model that aims to improve the quality of care for pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD) and their infants. The reports acknowledge that MOM Model beneficiaries faced complex and overlapping health, behavioral and social challenges that demanded flexible, trauma-informed care. The reports cite promising practices emerging that demonstrate how states can advance integrated care for pregnant and postpartum individuals with opioid use disorder in Medicaid by aligning services with patients’ full range of medical, behavioral and social needs.

AAPP members Michelle Geier, PharmD, APh, BCPP, FAAPP; Michelle Colvard, PharmD, BCPP; and Rebecca Hoss, PharmD, BCPP represented AAPP and psychiatric pharmacy in presenting a session on the important role of psychiatric pharmacists in treating and engaging patients with MOUD. Speakers detailed their practice models and the significant impact they make as psychiatric pharmacists in various settings including in public health, an outpatient SUD clinic, and a hospital system. We appreciate their contributions and advocacy on behalf of psychiatric pharmacy.

Each 30-minute webinar offers a dynamic, peer-driven discussion focused on complex substance use disorder cases. Free to AAPP members! Click the link to learn more and register.

ASAM has expanded its benzodiazepine tapering resource suite to support clinicians and patients.

AAPP supports the use of antipsychotics as the first line treatment for acute and maintenance treatment of schizophrenia. Use AAPP’s policy brief to support your own advocacy for this gold-standard treatment (member only resource).

This toolkit provides a resource for recognizing, understanding, and managing episodes of agitation and forms of aggression encountered in clinical practice.

The value and impact of psychiatric pharmacists takes center stage in this HealthWell Foundation feature article.

In early November, AAPP will be launching a 5.5 hour educational series on clozapine. Grant funded in partnership with the Schizophrenia & Psychosis Alliance, this program seeks to educate clinicians and expand the use of clozapine. News of this grant has also promoted the role of psychiatric pharmacists as seen in this article on HealthWell Foundation’s website. HealthWell is a non-profit that provides financial assistance for insurance and medications for illnesses such as schizophrenia. A special thanks for AAPP President Jolene Bostwick for so eloquently describing the value and impact of psychiatric pharmacists.

AAPP members Michelle Geier, PharmD, APh, BCPP, FAAPP; Michelle Colvard, PharmD, BCPP; and Rebecca Hoss, PharmD, BCPP represented AAPP and psychiatric pharmacy in presenting a session on the important role of psychiatric pharmacists in treating and engaging patients with MOUD. Speakers detailed their practice models and the significant impact they make as psychiatric pharmacists in various settings including in public health, an outpatient SUD clinic, and a hospital system. We appreciate their contributions and advocacy on behalf of psychiatric pharmacy.

Persisting high rates of mental health disorders in patients in opioid agonist treatment—Results from a 6-year longitudinal study

Use of stigmatizing language related to substance use disorders in media: A systematic review

Medications for Opioid Use Disorder in County Jails — Outcomes after Release

This study provides the first evidence that CM use in real-world health care settings is associated with reduced risk of mortality.

Richard J. Silvia, PharmD, BCPP discusses ways to communicate risks vs benefits of OTCs in patients with anxiety.

AAPP supports access to antidepressants for youth with moderate to severe symptoms of depression, anxiety, or OCD and reconsideration of the suicide boxed warning. Use AAPP’s policy brief to advocate for this gold-standard treatment.

Access valuable psychiatric treatment guideline and clinical pearl resources at AAPP

Collaborative practice agreements permit clinical pharmacists to provide expanded healthcare services to patients. Learn more in this 11-minute video.

Our newly launched, member-protected Policy Statements and Briefs webpage details AAPP’s stance on over 35 topics surrounding access to care, gold standard treatments, and needed policies to support access to care and psychiatric pharmacists. These policy statements are further supported by our advocacy fact sheets and 7 policy briefs, a new set of resources authored by our Rapid Action Task Force. Please check out these new resources and provide your feedback directly from the webpage.

Last week, the Senate passed a reauthorization of the SUPPORT Act in a rare show of bipartisanship. The SUPPORT Act reauthorizes key prevention, treatment and recovery programs for patients with substance use disorder, including programs to support the behavioral health workforce. Among the reauthorized programs are the Substance Use Disorder Treatment and Recovery (STAR) Loan Repayment Program, helping bolster the workforce by providing loan repayment opportunities for SUD treatment and recovery providers in the face of severe workforce shortages — as well as critical recovery efforts through the Building Communities of Recovery (BCOR) program and comprehensive opioid recovery centers. The bill now heads to President Trump’s desk for his signature.

Initiation and Dose of Methadone Monotherapy vs Combination Therapy, 2015 to 2023

Retention rates and cost-effectiveness of telehealth vs. in-person buprenorphine treatment for opioid use disorder (OUD)

AAPP has elected three members to the 2026-2028 Board of Directors. Congratulations to Drs. Cunningham, Campbell, and DiPaula!

This document features high-level key takeaways from the May 2025 workshop.

AAPP’s free resource document on Methamphetamine Use Disorder provides information on screening, diagnosis, intoxication, withdrawal, treatment, co-occurring psychiatric disorders, special populations, and harm reduction strategies.

Calling all psychiatric pharmacist rising stars. Nominate yourself or others for the AAPP Early Practitioner Award designed to recognizes future leaders within AAPP and Psychiatric Pharmacy. Nominations close 10/1/2025.

AAPP submitted comments on CMS’s CY 2026 Physician Fee Schedule Proposed Rule, encouraging the agency to strengthen behavioral health integration in primary care, expand telehealth flexibilities, and proceed cautiously with proposed changes to the 340B program.

AAPP’s new policy statements and briefs are rooted in evidence and AAPP’s mission. See how you can use them to advocate.

AAPP Board member Danielle Stutzman, PharmD, BCPP, represented psychiatric pharmacy in expressing concerns about study's potential to perpetuate stigmatization of vaccines and, in particular, ASD.

Exams can be daunting. Let us help! Register for the Developing Effective Test-Taking Skills webinar to sharpen your skills. #BCPP #examprep #psychpharmacy #AAPP

AAPP submitted comments on CMS’s CY 2026 Physician Fee Schedule Proposed Rule, encouraging the agency to strengthen behavioral health integration in primary care, expand telehealth flexibilities, and proceed cautiously with proposed changes to the 340B program. AAPP also responded to an embedded request for information on prescription drug monitoring programs (PDMP) requirements and as always, took the opportunity to encourage CMS to recognize psychiatric pharmacists as qualified health care professionals as well as create payment pathways for pharmacist-provided comprehensive medication management.

Carolanne Wartman, PharmD, BCPS, BCPP (she/her) discussing asking, advocating, and creating inclusive environments for LGBTQIA+ patients.

Approximately 60% of depression is treated in the primary care setting. Psychiatric pharmacists can utilize their knowledge and training to assist primary care providers in treating mental illness. Watch this video to learn more.

AAPP's pharmacist toolkit on Xylazine is intended to highlight both the evidence base available as well as strategies of clinical decision making used by expert clinicians.